Vischer: Anokion raises $35 million financing

Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based on innovation from the EPFL Life Sciences, Anokion is led by a diverse team of entrepreneurial scientists and experienced industry professionals, striving to transform treatment for autoimmune patients around the world.

VISCHER acted as legal advisor to Anokion in this transaction. The team included partner Matthias Staehelin (pictured), Vincent Reardon and Luzius Zumstein (all corporate/m&a).

Vischer: Anokion raises $35 million financing


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram